MedTrace Logo

CT and MRI in Prediction of Response in Patients With Gastric Cancer Following Neoadjuvant Chemotherapy and/or Immunotherapy

NCT04913896 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2021-06-04

No results posted yet for this study

Summary

This is a prospective and observational clinical study for seeking out a better way to predict the pathologic complete response (pCR) in patients with advanced gastric cancer (AGC) based on the post-neoadjuvant treatment Magnetic Resonance Imaging (MRI) and CT data. This study will help the surgeons to better formulate treatment regimens for gastric cancer in the clinical practice.

Conditions

  • Gastric Cancer
  • Magnetic Resonance Imaging
  • Tomography, X-Ray Computed
  • Neoadjuvant Immunotherapy
  • Neoadjuvant Chemotherapy

Interventions

DRUG

PD-1 inhibitor

SOX regimen for 3 cycles and/or PD-1 inhibitor before surgery

Sponsors & Collaborators

  • The First Hospital of Jilin University

    lead OTHER

Principal Investigators

  • quan wang, MD · The First Hospital of Jilin University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2022-10-01
Completion
2023-06-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04913896 on ClinicalTrials.gov